Home›Pirfenidone Capsule, 267 Mg

Pirfenidone Capsule, 267 Mg

Also known as: Esbriet

Pyridone

Route: Oral

Check Pirfenidone Capsule, 267 Mg Interactions →

3 interactions on record

Pirfenidone Capsule, 267 Mg has 3 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Enoxacin, Fluvoxamine, Ciprofloxacin. Patients taking Pirfenidone Capsule, 267 Mg should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 2
Moderate: 1

Major (2)

Pirfenidone Capsule, 267 Mg + Enoxacin— Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone a…
Pirfenidone Capsule, 267 Mg + Fluvoxamine— Strong CYP1A2 inhibitor significantly increases pirfenidone exposure. Concomitant use is not recommended; discontinue fl…

Moderate (1)

Pirfenidone Capsule, 267 Mg + Ciprofloxacin— 7 DRUG INTERACTIONS Moderate (e.g., ciprofloxacin) and strong inhibitors of CYP1A2 (e.g., fluvoxamine) increase systemic…

Pirfenidone Capsule, 267 Mg + Enoxacin⚠️Major

Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone administration and avoided during treatment.

Pirfenidone Capsule, 267 Mg + Fluvoxamine⚠️Major

Strong CYP1A2 inhibitor significantly increases pirfenidone exposure. Concomitant use is not recommended; discontinue fluvoxamine prior to pirfenidone administration or reduce pirfenidone to 267 mg three times daily.

Pirfenidone Capsule, 267 Mg + Ciprofloxacin🟡Moderate

7 DRUG INTERACTIONS Moderate (e.g., ciprofloxacin) and strong inhibitors of CYP1A2 (e.g., fluvoxamine) increase systemic exposure of pirfenidone and may alter the adverse reaction profile of pirfenidone. Consider dosage reduction with use of ciprofloxacin. Moderate CYP1A2 Inhibitors Concomitant administration of pirfenidone and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to pirfenidone [see Clinical Pharmacology ( 12.3 )] .

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.